At 100-thousand Euro per patient, per year, the health authority says Nivolumab, known as Opdivo, is too expensive.
But 34-year-old Jacinta Kelleher says it's her only chance of surviving kidney cancer.
Since her diagnosis three years ago she has endured numerous operations to remove tumours – resulting in the loss of one of her kidneys.
Jacinta says this new drug is her last chance.
